Fig. 7. Reducing dynein activity leads to reduced grk mRNA recovery. FRAP experiments were performed on grk^*GFP; tubGal4/+;UAS-Dmn/+ and grk^*GFP; dhc^6-10/6-12 egg chambers. Images of grk^*GFP (A,B), grk^*GFP; tubGal4/+;UAS-Dmn/+ egg (C,D) and grk^*GFP; dhc^6-10/6-12 (E,F) egg chambers during stages 6-7 (A,C,E) and late 8 to early 9 (B,D,F). (A,B) Properly localized grk^*GFP lines the posterior cortex of young egg chambers, whereas grk^*GFP forms a crescent around the oocyte nucleus at the dorsal anterior corner starting stage 8. In a UAS-Dmn background (C,D), there is mislocalized grk^*GFP in the oocyte cytoplasm accompanied by large aggregates that can also be seen in the nurse cells (arrow). Under these conditions, a significant proportion of grk^*GFP is capable of reaching its destination both at the posterior and dorsal-anterior corner. In hypomorphic alleles (E,F), grk^*GFP has a very diffuse localization during young stages and accumulates at the anterior cortex in later stages. Similar to (C,D), there are aggregates in both the nurse cell and oocyte cytoplasm. A defined area of fluorescent grk at the posterior and dorsal-anterior was bleached during FRAP experiments. (G) In control early stages (6-7), grk^*GFP has on average 67% fluorescence recovery and during mid-stages (l8 to e9) a 46% recovery during FRAP experiments, whereas by contrast a significant reduction occurs in both young and mid stages when dynein activity is compromised. When Dmn is overexpressed, recovery is reduced to 34% in stages 6-7 and 28% in l8-e9. Similarly, in the dynein hypomorphs, recovery is reduced to 24% in stage l8-e9 egg chambers. A minimum of five FRAP experiments were performed for each data point. Error bars represent standard deviations.